In a significant milestone for Alzheimer's disease diagnosis, the U.S. Food and Drug Administration has given the green light to Fujirebio Diagnostics' blood test, making it the first of its kind to effectively detect the condition. The test, known as Lumipulse, is set to revolutionize the diagnosis process by initially being used to rule out Alzheimer's, with positive results prompting further diagnostic evaluation.
Alzheimer's disease, a progressive neurodegenerative disorder impacting memory and cognitive functions, is defined by specific changes in the brain, including the accumulation of amyloid beta plaques that lead to the deterioration of critical neuronal communication pathways. Fujirebio's innovative test analyzes two key proteins in the blood, pTau217 and β-amyloid 1-42, and calculates a ratio between them. This ratio serves as a reliable indicator of amyloid plaque presence in the brain, a hallmark feature of Alzheimer's.
Previously, detecting these plaques typically required invasive procedures such as PET brain scans or spinal taps. However, Lumipulse simplifies the process by solely necessitating a blood draw, significantly enhancing patient convenience and comfort. FDA Commissioner Martin Makary expressed optimism about the potential impact of this new diagnostic tool in the wake of rising Alzheimer's prevalence.
Comparative evaluations led by researchers at Washington University School of Medicine identified Lumipulse and C2N Diagnostics' PrecivityAD2 as the top performers among several commercial blood tests for Alzheimer's. Additionally, the FDA has approved treatments such as Biogen and Eisai's Leqembi and Eli Lilly's Kisunla for Alzheimer's disease, underscoring the ongoing advancements in both diagnosis and therapeutic interventions for this debilitating condition.